Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research report on Wednesday, February 12th.

Aptose Biosciences Price Performance

Shares of APTO opened at $0.15 on Monday. The company has a 50-day moving average of $0.21 and a two-hundred day moving average of $0.31. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.01. The stock has a market cap of $9.02 million, a price-to-earnings ratio of -0.05 and a beta of 0.88.

Aptose Biosciences’s stock is scheduled to reverse split before the market opens on Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, February 25th.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.